Experimental HCV Drugs
Experimental HCV Drugs
APASL: Simeprevir Matches Telaprevir in Phase 3 Study, Gets Positive European Regulatory Opinion
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 25 March 2014 00:00
- Written by Janssen/Medivir
The new hepatitis C virus (HCV) protease inhibitor simeprevir has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization in the European Union, Janssen R&D announced this week. The recommendation was based on findings from a set of Phase 3 trials, some of which were presented at the Asian Pacific Association for the Study of the Liver (APASL) conference this month in Brisbane.
Advances in Hepatitis C Treatment: the Future Is Now [VIDEO]
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 24 March 2014 00:00
- Written by Gregory Fowler
As effective direct-acting antiviral drugs to treat hepatitis C come into widespread use and interferon-free therapy becomes a reality, patients, providers, and payers are now grappling with issues such as who should receive treatment and how to pay for the new medications.
CROI 2014/APASL 2014: Merck Combo Suppresses HCV in Monoinfected and Coinfected Patients
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 21 March 2014 00:00
- Written by Liz Highleyman
An all-oral combination of the HCV protease inhibitor MK-5172 and the NS5A inhibitor MK-8742, with or without ribavirin, demonstrated promising end-of-treatment viral suppression in HIV/HCV coinfected patients and high cure rates in people with hepatitis C alone, according to findings from the C-WORTHY study presented at recent conferences.
CROI 2014: Interferon-free BMS Combo Cures 90% of Genotype 1 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Monday, 24 March 2014 00:00
- Written by Liz Highleyman
An all-oral regimen of daclatasvir, asunaprevir, and BMS-791325 -- without interferon or ribavirin -- led to sustained response in approximately 90% of previously untreated hepatitis C patients, most with hard-to-treat genotype 1a, according to a study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.
APASL 2014: Latest Hepatitis C Treatments Offer Good News for HIV/HCV Coinfected People
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 21 March 2014 00:00
- Written by APASL
People coinfected with HIV and hepatitis C are at risk of faster liver disease progression, so they stand to benefit even more from new direct-acting antiviral therapies that could cure hepatitis C as effectively and be equally well-tolerated in HIV/HCV coinfected and HCV monoinfected patients, Gregory Dore said at the 23rd Conference of the Asian Pacific Association for the Study of the Liver (APASL 2014) last week in Brisbane.
More Articles...
- CROI 2014: Daclatasvir + Simeprevir Effective Against Hepatitis C Genotype 1b
- Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections
- Coverage of the 2014 Conference on Retroviruses and Opportunistic Infections
- CROI 2014: Simeprevir Cures Almost 80% of First-time HIV/HCV Coinfected Patients
Web Design and Development by